[go: up one dir, main page]

AU6773598A - Treatment of gastrointestinal disease with ppar modulators - Google Patents

Treatment of gastrointestinal disease with ppar modulators

Info

Publication number
AU6773598A
AU6773598A AU67735/98A AU6773598A AU6773598A AU 6773598 A AU6773598 A AU 6773598A AU 67735/98 A AU67735/98 A AU 67735/98A AU 6773598 A AU6773598 A AU 6773598A AU 6773598 A AU6773598 A AU 6773598A
Authority
AU
Australia
Prior art keywords
treatment
gastrointestinal disease
ppar modulators
ppar
modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU67735/98A
Inventor
Johan Auwerx
Michael R Briggs
Anne-Marie Lefebvre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Ligand Pharmaceuticals Inc
Original Assignee
Institut Pasteur
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur, Ligand Pharmaceuticals Inc filed Critical Institut Pasteur
Publication of AU6773598A publication Critical patent/AU6773598A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU67735/98A 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators Abandoned AU6773598A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4137297P 1997-03-26 1997-03-26
US60041372 1997-03-26
PCT/US1998/005852 WO1998043081A1 (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Publications (1)

Publication Number Publication Date
AU6773598A true AU6773598A (en) 1998-10-20

Family

ID=21916159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU67735/98A Abandoned AU6773598A (en) 1997-03-26 1998-03-25 Treatment of gastrointestinal disease with ppar modulators

Country Status (2)

Country Link
AU (1) AU6773598A (en)
WO (1) WO1998043081A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8588798A (en) 1997-07-25 1999-02-16 Institut Pasteur Human peroxisome proliferator activated receptor gamma (ppargamma) gene re gulatory sequences and uses therefor
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
CA2366281A1 (en) * 1999-03-11 2000-09-14 Nuclear Receptor Research Limited Novel ligands of nuclear receptors ppar's
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
PT1206457E (en) 1999-08-27 2004-03-31 Lilly Co Eli DIARIL-OXA (TIA) ZOL DERIVATIVES AND ITS USE AS PPARS MODULATORS
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1413331T3 (en) 2001-01-26 2007-12-10 Schering Corp Combinations of the peroxisome proliferator-activated receptor (PPAR) activator fenofibrate and the sterol absorption inhibitor ezetimibe for vascular indications
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
ATE331512T1 (en) 2001-01-26 2006-07-15 Schering Corp USE OF AZETIDINONE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF SITOSTEROLHEMIA
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
WO2002080899A1 (en) * 2001-03-30 2002-10-17 Eisai Co., Ltd. Remedial agent for digestive disease
JP2005504091A (en) 2001-09-21 2005-02-10 シェーリング　コーポレイション Treatment of xanthomas with azetidinone as a sterol absorption inhibitor
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
GB0127916D0 (en) * 2001-11-21 2002-01-16 Rowett Res Inst Method
US20040092499A1 (en) 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (en) 2003-03-07 2009-02-16 Schering Corporation AZETIDINONA COMPOSITE SUBSTITUTED, FORNULATIONS AND USES OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
EP1733237A2 (en) * 2004-03-26 2006-12-20 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara)
ITMI20041825A1 (en) * 2004-09-24 2004-12-24 Medestea Res & Production Srl RECEPTOR AGONISTS ACTIVATING THE PROLIFERATION OF PEROXYSOMES, USEFUL IN THE PREVENTION OR TREATMENT OF GASTRITIS
ITRM20050390A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
ITRM20050389A1 (en) 2005-07-22 2007-01-23 Giuliani Spa COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS.
IN2015DN00502A (en) 2006-01-18 2015-06-26 Evolva Sa
US20100273824A1 (en) 2007-01-18 2010-10-28 Evolva Sa Substituted 1,3-dioxanes and their uses
MX2009007670A (en) 2007-01-18 2011-11-18 Evolva Sa Substituted 1,3-dioxanes useful as ppar modulators.
WO2008104305A1 (en) * 2007-02-27 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Pygm as a biomarker for ppara modulators
UA107562C2 (en) 2008-12-05 2015-01-26 METHOD OF TREATMENT OF PSORIASIS
ES2630044T3 (en) 2009-02-16 2017-08-17 Nogra Pharma Limited Alkylamide compounds and uses thereof
JP5180978B2 (en) * 2010-02-01 2013-04-10 花王株式会社 Screening method for anti-obesity substances
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR102067848B1 (en) 2012-02-09 2020-01-17 노그라 파마 리미티드 Methods of treating fibrosis
MX2014012652A (en) 2012-04-18 2014-11-25 Nogra Pharma Ltd Methods of treating lactose intolerance.
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
MX2017008449A (en) 2014-12-23 2017-10-12 4D Pharma Res Ltd PIRINE POLYPEPTIDE AND IMMUNE MODULATION.
PL3065748T3 (en) 2014-12-23 2018-07-31 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
MX2017016529A (en) 2015-06-15 2018-03-12 4D Pharma Res Ltd Compositions comprising bacterial strains.
TWI759266B (en) 2015-06-15 2022-04-01 英商4D製藥研究有限公司 Use of compositions comprising bacterial strains
LT3206700T (en) 2015-06-15 2019-08-26 4D Pharma Research Limited COMPOSITIONS INCLUDING BACTERIAL STRAINS
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
MA45287A (en) 2015-11-20 2018-08-22 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
CN114712405A (en) 2016-03-04 2022-07-08 4D制药有限公司 Compositions comprising bacterial strains
TWI802545B (en) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MA48941A (en) 2017-05-22 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
JP6978514B2 (en) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited Composition containing bacterial strain
ES2841902T3 (en) 2017-06-14 2021-07-12 4D Pharma Res Ltd Compositions comprising bacterial strains
CN111107859B (en) 2017-06-14 2022-04-29 4D制药研究有限公司 Compositions comprising bacterial strains
CN110913876A (en) 2017-06-14 2020-03-24 4D制药研究有限公司 Compositions comprising bacterial strains of the genus Megacoccus and uses thereof
SMT202500054T1 (en) 2019-02-08 2025-03-12 Nogra Pharma Ltd Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
CN112168820B (en) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 Application of SRCAP ATPase inhibitor in colorectal cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2269897A (en) * 1992-08-13 1994-02-23 Merck Frosst Canada Inc Assay to detect peroxisome proliferator activity

Also Published As

Publication number Publication date
WO1998043081A1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
AU6773598A (en) Treatment of gastrointestinal disease with ppar modulators
AU5872696A (en) Endoscope
AU7268298A (en) Differential treatment of prosthetic devices
AU3075895A (en) Endoscope
AU1450900A (en) Methods of treatment of type 2 diabetes
AU7592998A (en) Modulators of tissue regeneration
AU5899798A (en) Aminoacyl sulfamides for the treatment of hyperproliferative disorders
AU6928098A (en) Optical modulator
AU3596199A (en) Treatment of celiac disease
AU8329498A (en) Diagnosis of edema
AU3322795A (en) Endoscope
AU1184399A (en) Therapeutic molecules
AU7058000A (en) 13 human colon and colon cancer associated proteins
AU6788498A (en) Novel human serine carboxypeptidase
AU7592398A (en) Human gp12 homolog
AU2105897A (en) Organic photoconductor and treatment therefor
AU8155898A (en) Human preprotachykinin b
AU7974798A (en) New human lysophospholipase
AU8557598A (en) Treatment of fluids
AU696976B2 (en) Effluent treatment
AU4124497A (en) Treatment of diabetes
AUPO495397A0 (en) Diagnosis of parasites
AUPO632997A0 (en) Diagnosis of parasites
AUPO948197A0 (en) Diagnosis of parasites
AU2002302012A1 (en) Chromim/biotin treatment of type II diabetes